ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaheen, M.
Right arrow Articles by Benincasa, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaheen, M.
Right arrow Articles by Benincasa, C
Eur Respir J 1994; 7: 2160-2164
Copyright © ERS Journals Ltd 1994


Clinical Trial

Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients

MZ Shaheen, JG Ayres, and C Benincasa

This study aimed to investigate and compare the incidence of metered-dose inhaler (MDI)-associated bronchoconstriction in an asthmatic population, following the use of three different MDIs. Two different placebo metered-dose inhaler preparations containing the same chlorofluorocarbons but differing in dispersant chemicals, one containing oleic acid (MDI-OA) and the other lecithin NF (MDI-L), were compared with a MDI containing salmeterol xinafoate (25 micrograms) and lecithin NF (MDI-S). The study population comprised 11,850 asthmatic patients, who were assigned to receive two puffs from one of the three inhalers: MDI-S (n = 3,948); MDI-L (n = 3,942); or MDI-OA (n = 3,960). Peak expiratory flow (PEF) was measured before and 5 min after inhalation. A 20% fall in PEF was defined as a clinically significant bronchoconstriction. Overall 180 (1.5%) patients demonstrated bronchoconstriction, 43 (1.1%) in the MDI-S group, 67 (1.7%) in the MDI-L group and 70 (1.8%) in the MDI-OA. A significantly lower incidence of bronchoconstriction was seen with the salmeterol xinafoate MDI compared to either of the other two preparations. The risk of acute bronchoconstriction was also shown to increase with age and with decreasing pretreatment PEF. The study has shown that acute bronchoconstriction is an uncommon adverse reaction following the use of metered-dose inhalers. In addition, the study suggests that one of the inert constituents currently within metered-dose inhalers is the likely source of the irritant leading to bronchoconstriction.


This article has been cited by other articles:


Home page
Toxicol SciHome page
D. Ball, J. Blanchard, D. Jacobson-Kram, R. O McClellan, T. McGovern, D. L Norwood, W. Vogel, R. Wolff, and L. Nagao
Development of Safety Qualification Thresholds and Their Use in Orally Inhaled and Nasal Drug Product Evaluation
Toxicol. Sci., June 1, 2007; 97(2): 226 - 236.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. I. Peters, D. C. Shelledy, A. P. Jones Jr., R. W. Lawson, C. P. Davis, and T. S. LeGrand
A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma
Chest, August 1, 2000; 118(2): 313 - 320.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. BISGAARD
Automatic Actuation of a Dry Powder Inhaler into a Nonelectrostatic Spacer
Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 518 - 521.
[Abstract] [Full Text]


Home page
DTBHome page
Using {beta}2-stimulants in asthma
DTB, January 1, 1997; 35(1): 1 - 4.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the European Respiratory Society.